KRAS and non-small cell lung carcinoma: Ladarixin is also being tested in combination with sotorasib—a targeted inhibitor of mutant K-RAS—in patients with KRAS G12C-mutant non-small-cell lung cancer (NSCLC) (ClinicalTrials.gov ID: NCT05815173).